Bicara Therapeutics Inc. Common Stock (BCAX) annual cash flow statement — 4-year operating, investing & financing history
| Cash from Operations | -116.24M | -106.83M | -74.75M | -45.63M | -32.08M |
| Operating CF Margin % | - | - | - | - | - |
| Operating CF Growth % | -181.08% | -42.92% | -63.83% | -42.25% | - |
| Net Income | -157.31M | -137.95M | -68M | -51.98M | -37.84M |
| Depreciation & Amortization | 355K | 406K | 56K | 19K | 10K |
| Stock-Based Compensation | 11.55M | 15.01M | 7.4M | 1.9M | 810K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 7.3M | 895K | -77K | 14.06M | 0 |
| Working Capital Changes | 21.87M | 14.81M | -14.13M | -9.62M | 4.95M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 19.7M | 0 | 2.64M | 0 | 0 |
| Cash from Investing | -217.51M | -318.45M | -9K | -586K | -192K |
| Capital Expenditures | -340K | -280K | -71K | -586K | -192K |
| CapEx % of Revenue | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - |
| Other Investing | 0 | 0 | 62K | 0 | 0 |
| Cash from Financing | 195.15M | 32.26M | 334.03M | 272.5M | 31.7M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 195.15M | 32.26M | 332.43M | 272.35M | 31.54M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 1.6M | 149K | 160K |
| Net Change in Cash | -138.6M | -393.03M | 259.27M | 226.28M | -573K |
| Free Cash Flow | -116.58M | -107.11M | -74.82M | -46.21M | -32.27M |
| FCF Margin % | - | - | - | - | - |
| FCF Growth % | -31.97% | -43.16% | -61.9% | -43.22% | - |
| FCF per Share | -1.92 | -1.96 | -1.37 | -0.89 | -0.62 |
| FCF Conversion (FCF/Net Income) | 0.74x | 0.77x | 1.10x | 0.88x | 0.85x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 1K |
Quick answers to the most common questions about buying BCAX stock.
Bicara Therapeutics Inc. Common Stock (BCAX) generated $-106.8M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Bicara Therapeutics Inc. Common Stock (BCAX) reported negative free cash flow of $107.1M in 2025, indicating capital requirements exceeded cash from operations.
Bicara Therapeutics Inc. Common Stock (BCAX) spent $0.3M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.